Neurocognitive aging and cardiovascular fitness Stan J. ColcombeArthur F. KramerPaige Scalf Prevention Pages: 9 - 14
Cell cultures from animal models of Alzheimer’s disease as a tool for faster screening and testing of drug efficacy Fabrizio TrincheseShumin LiuOttavio Arancio Assay And Animal Model Development Pages: 15 - 21
Novel approaches to models of Alzheimer’s disease pathology for drug screening and development Laura ShaughnessyBeth ChamblinRam Ramabhadran Assay And Animal Model Development Pages: 23 - 32
Validity of the Mindstreams™ computerized cognitive battery for mild cognitive impairment Tzvi DwolatzkyVictor WhiteheadHoward Chertkow Early Detection Pages: 33 - 44
Quantitative MRI assessment of Alzheimer’s disease Joseph A. HelpernJens JensenMaria F. Falangola Early Detection Pages: 45 - 48
Development and evaluation of iodinated tracers targeting amyloid plaques for SPECT imaging Mei-Ping KungZhi-Ping ZhuangHank F. Kung Early Detection Pages: 49 - 53
Development of a PET/SPECT agent for amyloid imaging in Alzheimer’s disease Yanming WangWilliam E. KlunkChester A. Mathis Early Detection Pages: 55 - 62
NAP mechanisms of neuroprotection Illana GozesRuth A. SteingartAvron D. Spier Neuroprotection Pages: 67 - 72
Progress toward identification of protease activity involved in proteolysis of apolipoprotein E in human brain Marcos A. MarquesPhillip A. OwensKeith A. Crutcher Neuroprotection Pages: 73 - 80
Structure-based functional design of chemical ligands for AMPA-subtype glutamate receptors Lei ZengKen ChenMing-Ming Zhou Neuroprotection Pages: 81 - 84
Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys Jerry J. BuccafuscoAlvin V. Terry Cognitive Enhancers Pages: 85 - 91
Role of acyl-coenzyme A Luigi PuglielliBlake C. EllisDora M. Kovacs Lipid-Lowering Therapies Pages: 93 - 96
Cholesterol, copper, and accumulation of thioflavine S-reactive Alzheimer’s-like amyloid β in rabbit brain D. Larry Sparks Lipid-Lowering Therapies Pages: 97 - 104
EFRH-phage immunization of Alzheimer’s disease animal model improves behavioral performance in morris water maze trials Vered LavieMaria BeckerBeka Solomon Immunotherapy Pages: 105 - 113
Aminopyridazines attenuate hippocampus-dependent behavioral deficits induced by human β-amyloid in a murine model of neuroinflammation Jeffrey M. CraftLinda J. Van EldikD. Martin Watterson Neuroinflammation Pages: 115 - 122
Down-regulation of amyloid precursor protein by peptide nucleic acid in vivo Mona BoulesKatrina WilliamsElliott Richelson Anti-Amyloid Pages: 123 - 128
FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein Lee Jae MorseSandra M. PaytonJack T. Rogers Anti-Amyloid Pages: 129 - 136
Amyloid precursor protein compartmentalization restricts β-amyloid production Swetal GandhiLorenzo M. RefoloKumar Sambamurti Anti-Amyloid Pages: 137 - 143
Drug discovery Jonathan D. SmithEnakshi ChakrabartiJustine A. Levin-Allerhand Anti-Amyloid Pages: 145 - 147
Transforming growth factor-β signaling pathway as a therapeutic target in neurodegeneration Tony Wyss-Coray Anti-Amyloid Pages: 149 - 153
β-synuclein-derived peptides with neuroprotective activity Manfred WindischBirgit Hutter-PaierRobert Wronski Anti-Amyloid Pages: 155 - 165
Novel glycosaminoglycan precursors as antiamyloid agents Robert KisilevskyWalter A. SzarekSandra Marone Anti-Amyloid Pages: 167 - 172